ROCKVILLE, Md., Nov. 6, 2014 /PRNewswire/ -- Synthetic Biologics,
Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies
for serious infections and diseases, with a focus on protecting the
microbiome, announced today that it intends to release
its financial results for the three and nine months ended
September 30, 2014 on Friday, November 14, 2014. The Company will hold
an investor conference call on Friday,
November 14th, at 8:30
a.m. EST.
During the call, Jeffrey Riley,
Synthetic Biologics' Chief Executive Officer, will provide an
update on the Company's C. difficile, C-IBS and Pertussis
programs, and a review of upcoming milestones for the Phase 2
Trimesta™ program for the treatment of
relapsing-remitting multiple sclerosis (MS). C. Evan Ballantyne, Synthetic Biologics' Chief
Financial Officer, will review the Company's financial results for
the three and nine months ended September
30, 2014.
Interested parties should call 1-888-347-5280 (U.S. toll free),
1-855-669-9657 (Canada toll free),
or +1 412-902-4280 (International), fifteen minutes before the
start of the call to register. Registered callers on the toll free
line may ask to be placed in the queue for the Question &
Answer Session. The call will also be webcast over the Internet at
http://www.videonewswire.com/event.asp?id=100975. If you are
unable to participate during the live conference call, the webcast
will be available for replay at the same URL,
http://www.videonewswire.com/event.asp?id=100975, for 30 days after
the call.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage
biotechnology company developing pathogen-specific therapies for
serious infections and diseases, with a focus on protecting the
microbiome. The Company is developing an oral biologic to protect
the gastrointestinal (GI) microflora from the effects of
intravenous (IV) antibiotics for the prevention of C.
difficile infection, an oral treatment to reduce the impact of
methane producing organisms on constipation-predominant irritable
bowel syndrome (C-IBS) and a monoclonal antibody combination for
the treatment of Pertussis. In addition, the Company is developing
a Phase 2 oral estriol drug for the treatment of
relapsing-remitting multiple sclerosis (MS) and cognitive
dysfunction in MS. For more information, please visit Synthetic
Biologics' website at www.syntheticbiologics.com.
SOURCE Synthetic Biologics, Inc.